Inhibition of the Class II HMG-CoA reductase of Pseudomonas mevalonii

被引:15
|
作者
Hedl, M [1 ]
Rodwell, VW [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
关键词
HMG-CoA reductase; Class IIHMG-CoA reductase; Pseudomonas mevalonii; isoprenoid biosynthesis; statin drug; Lovastatin;
D O I
10.1110/ps.03597504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are two structural classes of HMG-CoA reductase, the third enzyme of the mevalonate pathway of isopentenyl diphosphate biosynthesis-the Class I enzymes of eukaryotes and the Class II enzymes of certain eubacteria. Structural requirements for ligand binding to the Class II HMG-CoA reductase of Pseudomonas mevalonii were investigated. For conversion of mevalonate to HMG-CoA the -CH3, -OH, and -CH2COO- groups on carbon 3 of mevalonate were essential for ligand recognition. The statin drug Lovastatin inhibited both the conversion of HMG-CoA to mevalonate, and the reverse of this reaction. Inhibition was competitive with respect to HMG-CoA or mevalonate and noncompetitive with respect to NADH or NAD(+). K-i values were millimolar. The over 10(4)-fold difference in statin K-i values that distinguishes the two classes of HMG-CoA reductase may result from differences in the specific contacts between the statin and residues present in the Class I enzymes but lacking in a Class II HMG-CoA reductase.
引用
收藏
页码:1693 / 1697
页数:5
相关论文
共 50 条
  • [21] HMG-COA REDUCTASE INHIBITORS
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1988, 40 (06): : 477 - 477
  • [22] HMG-COA REDUCTASE INHIBITORS
    GRUNDY, SM
    JOURNAL OF INTERNAL MEDICINE, 1990, 228 (03) : 201 - 205
  • [23] HMG-CoA reductase inhibitors
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (01) : 77 - 78
  • [24] HMG-COA REDUCTASE INHIBITORS, A NOVEL CLASS OF HYPOLIPIDEMIC AGENTS
    SMITH, RL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1987, 194 : 91 - MEDI
  • [25] Amelioration of angiotensin II-induced cardiac injury by HMG-CoA reductase inhibition
    Dechend, R
    Fiebeler, A
    Park, JK
    Muller, DN
    Theuer, J
    Mervaala, EM
    Bieringer, M
    Schmidt, F
    Gulba, D
    Dietz, R
    Luft, FC
    Haller, H
    HYPERTENSION, 2000, 36 (04) : 683 - 683
  • [26] REGULATION OF HMG-COA REDUCTASE BY A NEW CLASS OF NONCOMPETITIVE INHIBITORS
    STACPOOLE, PW
    HARWOOD, HJ
    VARNADO, CE
    JOURNAL OF LIPID RESEARCH, 1983, 24 (10) : 1413 - 1413
  • [27] Amelioration of angiotensin II-induced cardiac injury by HMG-CoA reductase inhibition
    Dechend, R
    Fiebeler, A
    Park, JK
    Mueller, DN
    Theuer, J
    Mervaala, E
    Bleringer, M
    Schmidt, F
    Gulba, DC
    Dietz, R
    Luft, FC
    Haller, H
    CIRCULATION, 2000, 102 (18) : 135 - 135
  • [28] Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism
    Han, Ki Hoon
    KOREAN CIRCULATION JOURNAL, 2018, 48 (11) : 951 - 963
  • [29] QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition
    Ancuceanu, Robert
    Popovici, Patriciu Constantin
    Draganescu, Doina
    Busnatu, Stefan
    Lascu, Beatrice Elena
    Dinu, Mihaela
    PHARMACEUTICALS, 2024, 17 (11)
  • [30] Responses to the inhibition of HMG-CoA reductase: A comparison of simvastatin and atorvastatin
    Bergstrom, JD
    Bostedor, RG
    Rew, DJ
    Geissler, WM
    Wright, SD
    Chao, YS
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 121 - 121